glp 1 suicidal ideation Association of glucagon-like peptide-1 receptor agonists with and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study | Diabetologia GLP-1 diabetes drugs not linked

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

At least six films of each formulation should be used in this study so that the mean and standard deviation can be determined

A multicenter observational study in Japan published in the Frontiers in Clinical Diabetes and Healthcare found that individuals with type 2 diabetes taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) showed reduced external eating scores after 12 months of therapy Their blood sugar levels, body weight, and body fat percentage also decreased significantly Emotional and restrained eating showed only transient changes

Adults age 65 and older also reported more regular engagement in all healthy behaviors